Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone’s impact on TLR4-mediated inflammation - Scorecard - MDSpire

Early immune responses to intradermal lipopolysaccharide in healthy volunteers: prednisolone’s impact on TLR4-mediated inflammation

  • By

  • Thomas P. Buters

  • Digna T. de Bruin

  • Pieter W. Hameeteman

  • Wouter ten Voorde

  • Hendrika W. Grievink

  • Michelle Osse

  • Marieke L. de Kam

  • Jeffrey Damman

  • Thierry P. P. van den Bosch

  • Elsa Neubert

  • Robert Rissmann

  • Jacobus Burggraaf

  • Naomi Klarenbeek

  • Manon A. A. Jansen

  • Matthijs Moerland

  • May 20, 2026

  • 0 min

Share

Clinical Scorecard: Initial Immune Reactions to Intradermal Lipopolysaccharide in Healthy Subjects: The Role of Prednisolone in Modulating TLR4-Driven Inflammation

At a Glance

CategoryDetail
Condition
Key Mechanisms
Target PopulationHealthy male volunteers aged 18-45.
Care Setting

Key Highlights

  • Add significance of IL-8, IL-6, and IL-1β peaks.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Monitor IL-8, IL-6, and IL-1β levels post-LPS injection.

      Risks

        Patient & Prescribing Data

        Oral prednisolone administered at a dosage of X mg for 2.5 days prior to LPS challenge.

        Clinical Best Practices

        • Evaluate new anti-inflammatory therapies targeting IL-1β and NET formation, such as drug Y and drug Z.

        Related Resources & Content

        Original Source(s)

        Related Content